Figure 5.
OS according to IDH2 mutational status in ELN 2017 intermediate- and adverse-risk patients. Kaplan-Meier plots for OS of patients with AML within the ELN 2017 intermediate- and adverse-risk group in regard to mutated IDH2-R140 (blue), mutated IDH2-R172 (green), and WT IDH (orange); time in months.

OS according to IDH2 mutational status in ELN 2017 intermediate- and adverse-risk patients. Kaplan-Meier plots for OS of patients with AML within the ELN 2017 intermediate- and adverse-risk group in regard to mutated IDH2-R140 (blue), mutated IDH2-R172 (green), and WT IDH (orange); time in months.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal